What should you know about lutetium 177 PSMA therapy?

PSMA is a protein found on many prostate cancer cells. A carrier molecule guides lutetium 177 towards cells showing PSMA, where the radiation can damage them. A scan is usually used to check whether the cancer has enough PSMA for this approach to be considered. The medicine is given through an intravenous line in a specialist setting. It may be offered when prostate cancer has progressed despite earlier treatments, but the decision depends on scan findings, kidney function, blood counts and the wider treatment history.

Your nuclear medicine team will explain hydration, blood tests, medicines and any temporary contact precautions required after treatment. Follow the written instructions about fluids, bathroom hygiene, laundry and close contact because small amounts of radioactivity leave the body over time. Keep scheduled blood tests so the team can monitor marrow, kidneys and other organs. Mention dry mouth, nausea, reduced appetite, tiredness or changes in urination; supportive treatment can make these problems easier to manage.

Call the treatment team promptly for fever, unusual bruising or bleeding, very low urine output, persistent vomiting, severe weakness, or difficulty keeping fluids down. Seek emergency care for severe breathlessness, chest pain, fainting, confusion, or a serious allergic reaction with facial or throat swelling. Follow the radiation-safety contact number supplied by your centre if you are unsure whether a symptom or possible exposure needs advice.

Ask what the PSMA scan shows, why this treatment is suitable now, and how response will be checked. Ask how kidney function and blood counts affect eligibility, what side effects are expected, and how dry mouth can be managed. Confirm the home safety instructions, travel advice, contact precautions and the number to call outside clinic hours.